Physician profile
Atef Mousa
NPI 1891006565
$6,522.35
in general payments reported to CMS, 2019-2025
34 companies · $562 in 2025
The $562 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $577 · 2021: $923 · 2022: $840 · 2023: $1,313 · 2024: $1,639 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,625.19 | 2019-2025 | Lifevest |
| Abbvie INC. | $754.55 | 2019-2023 | |
| Gilead Sciences, INC. | $469.95 | 2019-2023 | Epclusa |
| Amgen INC. | $411.99 | 2023-2024 | Evenity, Tepezza, Repatha |
| Janssen Pharmaceuticals, INC | $371.88 | 2019-2021 | |
| Shionogi INC | $356.79 | 2023-2025 | Fetroja |
| E.R. Squibb & Sons, L.L.C. | $270.63 | 2019-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $238.83 | 2022-2025 | Airsupra, Farxiga |
| Ferring Pharmaceuticals INC. | $184.28 | 2024 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.00 | 2022-2025 | Jardiance |
| Edwards Lifesciences Corporation | $127.73 | 2023 | Sapien 3 Ultra Resilia |
| Melinta Therapeutics, LLC | $125.00 | 2022 | |
| Organogenesis INC. | $125.00 | 2023 | Puraply Antimicrobial |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $125.00 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124.99 | 2019 | |
| Alnylam Pharmaceuticals INC. | $124.99 | 2024 | Amvuttra |
| La Jolla Pharmaceutical Company | $121.81 | 2023 | Xacduro |
| Bayer Healthcare Pharmaceuticals INC. | $120.17 | 2023 | |
| Paratek Pharmaceuticals, INC. | $117.32 | 2022-2024 | Nuzyra |
| Dexcom, INC. | $77.18 | 2023-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $72.74 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $67.72 | 2024 | Watchman Flx |
| Ucb, INC. | $40.73 | 2024 | Briviact |
| Grifols USA, LLC | $28.69 | 2025 | Prolastin-C Liquid |
| Lundbeck LLC | $27.61 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $25.06 | 2025 | Austedo Xr |
| Ascensia Diabetes Care US INC. | $23.11 | 2024 | |
| Viatris Specialty LLC | $18.20 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $17.90 | 2020 | |
| Aimmune Therapeutics, INC. | $16.75 | 2024 | |
| Astellas Pharma US INC | $16.32 | 2024 | Cresemba |
| Irhythm Technologies, INC. | $14.33 | 2024 | Zio Monitor, Zio Xt Patch |
| Allergan, INC. | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atef Mousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.